Why Is RECURSION PHARMACEUT A (RXRX) Stock Up Today?

Recursion Pharmaceuticals (RXRX) shares rose 11.23% to $4.16, marking the company’s best single-day performance in over a year. The primary driver was a strategic milestone with Sanofi, which selected its first drug development candidate under their collaboration agreement. This event triggered a $10 million payment to Recursion and signaled potential Phase 1 trials in 2027.

What Happened

Sanofi exercised its option for the first immunology drug candidate from Recursion’s AI-driven platform. This selection triggered a $10 million milestone payment and established a pathway for Phase 1 clinical trials to begin in 2027. Simultaneously, Recursion announced a $200 million common stock offering of 61,540,000 shares at $3.25 per share to strengthen its balance sheet. The dual news flow created a mixed market reaction, with the stock initially dipping on the equity raise before rallying on the strategic validation from Sanofi.

Cathie Wood’s ARK Investment Management purchased 4.2 million shares of Recursion during the session. This move was part of a broader biotech portfolio shuffle where ARK accumulated positions in several names. The company remains unprofitable with a trailing twelve-month EPS of negative $1.02 and revenue down 15.1%. Analysts at Seeking Alpha maintained a Hold rating, citing limited near-term catalysts despite the pipeline progress.

What The Data Shows

The stock printed a fresh 52-week low on October 15, 2026, before reversing sharply. Over the preceding eight sessions, the share price had declined 7.2% from $4.63 to $4.30. The 52-week range stands between $2.77 and $7.18, placing the current price in the lower half of that spectrum. Recent insider activity shows five sales totaling $644,000 over the last 90 days, with no recorded buys. Directors Blake Borgeson and Robert Hershberg sold shares on October 6, while CEO Najat Khan sold on September 8.

What To Watch

Investors will monitor the execution of the $200 million equity offering and the timing of the Phase 1 trials for the Sanofi-selected candidate. The company’s ability to convert this strategic partnership into tangible clinical data will be the next key metric for valuation.